The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | VLS-101 in heavily pretreated MCL and DLBCL
Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a Phase I study aiming to evaluate the clinical efficacy and safety of VLS-101 in previously treated patients with ROR1-expressing tumors. Over the course of the trial, few adverse events were reported, none of them severe. The objective tumor responses were observed in 47% of patients with mantle cell lymphoma (MCL) and 80% of patients with diffuse large B-cell lymphoma (DLBCL), with some patients achieving a complete response. The results of this study confirm the tumor selectivity and predictable safety profile of VLS-101, which is consistent with other MMAE-containing antibody-drug conjugates (ADCs). The observed response rates provide clinical proof of concept for targeting ROR1 with VLS-101. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Michael Wang has received grants from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, Juno, Loxo Oncology, VelosBio, BioInvent, Kite Pharma, Verastem, BeiGene, Eli Lilly, InnoCare and Molecular Templates; has received personal fees from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, OMI, Pulse Biosciences, Juno, Loxo Oncology, VelosBio, Targeted Oncology, Kite Pharma, Guidepoint Global, BeiGene, InnoCare and Oncternal; has received non-financial support from Pharmacyclics, Celgene, Janssen and OMI.
